While the surge in U.S. sales of Fruzaqla is positive, the significant drop in net profits due to a high base effect from a previous licensing deal has tempered investor enthusiasm. The company's focus on innovative drugs and potential divestment of its traditional Chinese medicine business could lead to long-term growth, but the short-term impact on the stock price is likely neutral.